Oxitec
Latest round
- Series B
Last raised
- Sep 2007
Total raised
- $5.6M
Investors
- 3
About Oxitec
Oxitec Ltd. specializes in innovative biological solutions for controlling pest populations that threaten public health and agriculture.Founded in 2002, Oxitec Ltd. is headquartered in Abingdon, UK, and is known for its development of genetically modified organisms aimed at controlling pest populations. The company has undergone strategic pivots to enhance its focus on public health, particularly in combating diseases transmitted by mosquitoes. The CEO team includes Grey Frandsen, Hadyn Parry, and Stephan Gerth.00 mn from the Bill & Melinda Gates Foundation on April 13, 2022.Oxitec develops innovative biological solutions aimed at controlling pest populations that threaten public health and agricultural productivity. The company's core offerings include the Friendly™ platform, which employs genetically modified organisms to reduce populations of disease-carrying mosquitoes such as Aedes aegypti, responsible for transmitting dengue, Zika, and chikungunya viruses. Additionally, Oxitec is expanding its efforts to target malaria-carrying mosquitoes, enhancing its public health initiatives across multiple continents including Africa, North America, and South America. In the agricultural sector, Oxitec's technology is applied against various crop-damaging pests, utilizing its Friendly™ platform to mitigate challenges posed by agricultural threats globally.70. The company’s revenue model is structured around partnerships and collaborations with public health agencies and agricultural stakeholders, focusing on impact-driven solutions for pest control. Transactions typically involve contractual agreements with government entities and non-governmental organizations, facilitating the deployment of their genetically modified products in targeted regions. Pricing structures for Oxitec’s services are determined based on project scope and client needs, encompassing comprehensive service agreements that integrate their Friendly™ mosquito and agricultural pest control solutions.00 mn from the Bill & Melinda Gates Foundation to advance its anti-malaria program. Additionally, the company is looking to expand its operations into new geographic regions, particularly targeting areas in Africa and South America by the end of 2023, enhancing its public health initiatives to combat mosquito-borne diseases.
Who invested in Oxitec
3 investors across 2 rounds
See all investors in Oxitec
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Oxitec
Who invested in Oxitec?
Oxitec has 3 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Oxitec raised?
Oxitec has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Oxitec last raise money?
Oxitec's most recent round on record is a Series B, in Sep 2007.
What does Oxitec do?
Oxitec is a biotechnology company.
Where is Oxitec headquartered?
Oxitec is headquartered in Abingdon, UK.
Which VCs invest in companies like Oxitec?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at Oxitec's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Oxitec? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.